Successful Case
"
Corporate Solutions
Top 30 antitumormedicijnen in 2023 (in miljard dollar)
Top 30 antitumormedicijnen in 2023 (in miljard dollar)
| - Nee, dat is niet waar. | Naam van het geneesmiddel | Onderneming | Belangrijkste indicaties | Verkoop | Groeipercentage |
| 1 |
Kleefdier (pembrolizumab) |
MSD | Melanoma, NSCLC, Blaaskanker, HNC | 25.01 | 190,5% |
| 2 |
Opdivo (nivolumab) |
BMS/ONO | Melanoma, NSCLC, HNC | 10.04 | 90,0% |
| 3 |
Darzalex (daratumumab) |
Johnson & Johnson | Multiple myeloom, AL-amyloïdose | 9.74 | 220,2% |
| 4 |
Imbruvica (ibrutinib) |
Abbvie/Joshnson | CLL/SLL, MCL, GVHD | 6.86 | -17,9% |
| 5 |
Revlimid (lenalidomide) |
BMS | MM, MDS, MCL, FL | 6.10 | - 39,0% |
| 6 |
Vlees (osimertinib) |
Astrazeneca | T790M NSCLC | 5.80 | 70,0% |
| 7 |
Xtandi (enzalutamide) |
Astellas | Prostaatkanker | 5.07 | 40,3% |
| 8 |
Iberische (palbociclib) |
Pfizer | Borstkanker | 4.75 | -6,0% |
| 9 |
Jakafi (ruxolitinib) |
Incyte/Norvatis | Myelofibrose, PV | 4.31 | 80,7% |
| 10 |
Imfinzi (durvalumab) |
Astrazeneca | Urotheelcarcinoom, NSCLC, SCLC enz. | 4.24 | 520,0% |
| 11 |
Perjeta (Pertuzumab) |
Roche | HER2+ borstkanker | 4.21 | 10,0% |
| 12 |
Tecentriq (atezolizumab) |
Roche | Urotheelcarcinoom, NSCLC, TNBC | 4.21 | 90,0% |
| 13 |
Verzenio (abemaciclib) |
Eli Lilly | Borstkanker | 3.86 | 560,0% |
| 14 |
Pomalyst (pomalidomide) |
BMS | Multiple myeloom | 3.44 | -2,0% |
| 15 |
Lynparza (olaparib) |
Astrazeneca/MSD | Eierstokkanker, Borstkanker, Alvleesklierkanker, Prostaatkanker | 2.81 | 70,0% |
| 16 |
Eenheid (trastuzumab deruxtecan) |
Daiichi Sankyo/AZ | HER2+ borstkanker, HER2- lage borstkanker | 2.57 | 1040,8% |
| 17 |
Calquentie (acalabrutinib) |
Astrazeneca | Mantlecellimfoom, CLL/SLL | 2.51 | 220,0% |
| 18 |
Erleada (apalutamide) |
Johnson & Johnson | Prostaatkanker | 2.39 | 260,9% |
| 19 |
Venclexta (venetoclax) |
Abbvie. | CLL, AML | 2.29 | 130,9% |
| 20 |
Revolade/Promacta Ik heb geen idee. |
Norvatis | Trombocytopenie | 2.27 | 100,0% |
| 21 |
Yervoy (ipilimumab) |
BMS | Melanoma, RCC, CRC | 2.24 | 50,0% |
| 22 |
Kadcyla (trastuzumab Emtansine) |
Roche | HER2+ borstkanker | 2.19 | 40,0% |
| 23 |
Xgeva (denosumab) |
Amgen | Metastase van vaste tumoren in bot | 2.11 | 50,0% |
| 24 |
Kiskali (Ribociclib) |
Norvatis | HR+ borstkanker | 2.08 | 750,0% |
| 25 |
Lenvima (lenvatinib) |
Eisai/MSD | DTC, HCC, endometriumcarcinoom | 2.01 | 80,4% |
| 26 |
Sprycel (dasatinib) |
BMS | ALL, CML | 1.93 | - 11,0% |
| 27 |
Tafinlar+Mekinist (dabrafenib+trametinib) |
Norvatis | Melanoma, NSCLC, ATC | 1.92 | 110,0% |
| 28 |
Tasigna (nilotinib) |
Norvatis | CML | 1.85 | -3,0% |
| 29 |
Herceptine (trastuzumab) |
Roche | HER2+ borstkanker | 1.82 | -16,0% |
| 30 |
Avastine (bevacizumab) |
Roche | CRC, borstkanker, longkanker, eierstokkanker enz. | 1.76 | -19,0% |
